title: Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel-an Indirect Comparison.
abstract: BACKGROUND
  This study aims to make an indirect comparison between enzalutamide and abiraterone acetate for mCRPC post-docetaxel.
  
  
  METHODS
  A search for published phase 3 trials was performed with PubMed. Indirect comparisons of enzalutamide (AFFIRM) to abiraterone acetate (COU-AA-301) on outcomes overall survival (OS), time to prostate-specific-antigen (PSA) progression, radiographic progression-free survival (PFS), and PSA response were constructed in the context of log-linear regression models.
  
  
  RESULTS
  There was no statistically significant difference in OS (hazard ratio (HR) 0.85, 95% CI 0.68-1.07). However, there was some evidence that enzalutamide may outperform abiraterone acetate with respect to secondary outcomes: time to PSA progression (HR 0.40, 95% CI 0.30-0.53), radiographic PFS (HR 0.61, 95% CI 0.50-0.74), and PSA response rates (RRs) (OR 10.69, 95% CI 3.92-29.20).
  
  
  CONCLUSIONS
  While there was no statistically significant difference in OS, enzalutamide may be advantageous for secondary endpoints. Findings of this indirect comparison serve to be hypothesis-generating for future head-to-head trials.
authors.affiliation: Health Services and Systems Research, Duke-NUS Graduate Medical School, Singapore.
authors.forename: Pui S
authors.initials: PS
authors.lastname: Tan
authors.affiliation: Centre for Quantitative Medicine, Office of Clinical Sciences, Duke-NUS Graduate Medical School, Singapore. ; Department of Statistics and Applied Probability, National University of Singapore, Singapore.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Haaland
authors.affiliation: Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.
authors.forename: Alberto J
authors.initials: AJ
authors.lastname: Montero
authors.affiliation: Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.
authors.forename: Christos E
authors.initials: CE
authors.lastname: Kyriakopoulos
authors.affiliation: Hospital do Coração Cancer Center (HCor Onco), Brazil. ; Centro Paulista de Oncologia, Brazil. ; Oncoclinicas do Brasil, Brazil. ; Johns Hopkins University, Baltimore, MD, USA.
authors.forename: Gilberto
authors.initials: G
authors.lastname: Lopes
keywords: abiraterone acetate; enzalutamide; mCRPC; metastatic castration-resistant prostate cancer; post-docetaxel